Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma × zipalertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 1 Lung Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

pembrolizumab 11 Cisplatin 11 Specimen Handling 8 Magnetic Resonance Spectroscopy 8 durvalumab 4 Platinum 4 Pemetrexed 4 Paclitaxel 4 Cyclophosphamide 4 1,2-diaminocyclohexaneplatinum II citrate 4 fludarabine 3 cemiplimab 3 Radiotherapy, Intensity-Modulated 3 Radiotherapy 3 Oxaliplatin 3 Nivolumab 3 Fluorouracil 3 Carboplatin 3 Biopsy 3 poly ICLC 2 osimertinib 2 cabozantinib 2 atezolizumab 2 Heavy Ion Radiotherapy 2 Gemcitabine 2 Drug Therapy 2 Docetaxel 2 Cetuximab 2 Capecitabine 2 zipalertinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05967689 2026-03-10

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡